Skip to main content

RT @AkhilSoodMD: Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi,

Social Author Name
Akhil Sood MD
Tweet Content
Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×